Official UK procurement notice
Provision of: Amyloidosis Networked Model of Care
Authority: NHS England (Central government)
What is being bought4 lots · detail below
Published requirement descriptionNHS England, Highly Specialised Services (referred to as the Commissioner) is awarding to suitably qualified and experienced providers for the Provision of Amyloidosis Networked Model of Care services, following a Competitive Process. NHS Arden and Greater East Midlands CSU (AGCSU) is acting as an agent for and on behalf of the Commissioner and is supporting the provider selection process.<br/><br/>Amyloidosis is the name for a group of rare, serious conditions caused by a build-up of an abnormal protein, called amyloid, in organs and tissues throughout the body. The build-up of amyloid proteins (deposits) can make it difficult for the organs and tissues to work properly.<br/><br/>The key objectives of the Competitive Process was to commission a networked model of care for Amyloidosis services to establish four regional centres under this initial process. This is to ensure a good level of access in place that is able to meet the expected demand for the service. <br/><br/>The regional centres are proposed to be in the:<br/>
- Lot 2 - Midlands<br/>
- Lot 3 - North West
CPV: Health and social work services
Lots and requirements (4)Procurement structure
4 lots · all with a published value (£5,040,000 together) · a supplier may bid for at most 1 of them · same evaluation weights on every lotLot #1South WestCancelled South WestPublished value£1,260,000
NHS England, Highly Specialised Services (referred to as the Commissioner) is not awarding to any provider for the Lot (1) in the South West.<br/><br/>Amyloidosis is the name for a group of rare, serious conditions caused by a build-up of an abnormal protein, called amyloid, in organs and tissues throughout the body. The build-up of amyloid proteins (deposits) can make it difficult for the organs and tissues to work properly.<br/><br/>The key objectives of the Competitive Process was to commission a networked model of care for Amyloidosis services to establish four regional centres under this initial process. This is to ensure a good level of access in place that is able to meet the expected demand for the service.
Lot #2MidlandsAwarded East Midlands, West MidlandsPublished value£1,260,000
NHS England, Highly Specialised Services (referred to as the Commissioner) is awarding to suitably qualified and experienced provider for the Provision of Amyloidosis Networked Model of Care services, following a Competitive Process. NHS Arden and Greater East Midlands CSU (AGCSU) is acting as an agent for and on behalf of the Commissioner and is supporting the provider selection process.<br/><br/>Amyloidosis is the name for a group of rare, serious conditions caused by a build-up of an abnormal protein, called amyloid, in organs and tissues throughout the body. The build-up of amyloid proteins (deposits) can make it difficult for the organs and tissues to work properly.<br/><br/>The key objectives of the Competitive Process was to commission a networked model of care for Amyloidosis services to establish regional centres under this initial process. This is to ensure a good level of access in place that is able to meet the expected demand for the service.<br/><br/>The regional centre to be awarded is for:<br/><br/>
- Lot 2 - Midlands
Lot #3North WestAwarded North WestPublished value£1,260,000
NHS England, Highly Specialised Services (referred to as the Commissioner) is awarding to suitably qualified and experienced provider for the Provision of Amyloidosis Networked Model of Care services, following a Competitive Process. NHS Arden and Greater East Midlands CSU (AGCSU) is acting as an agent for and on behalf of the Commissioner and is supporting the provider selection process.<br/><br/>Amyloidosis is the name for a group of rare, serious conditions caused by a build-up of an abnormal protein, called amyloid, in organs and tissues throughout the body. The build-up of amyloid proteins (deposits) can make it difficult for the organs and tissues to work properly.<br/><br/>The key objectives of the Competitive Process was to commission a networked model of care for Amyloidosis services to establish four regional centres under this initial process. This is to ensure a good level of access in place that is able to meet the expected demand for the service.<br/><br/>The regional centre is to be in the:<br/><br/>
- Lot 3 - North West
Lot #4North East and YorkshireCancelled North East, Yorkshire & HumberPublished value£1,260,000
NHS England, Highly Specialised Services (referred to as the Commissioner) is not awarding under Lot 4 (North East and Yorkshire). As no bids were received.
What it takes to wini
How this buyer will score bids.
The evaluation criteria and weights exactly as published on the notice, grouped by family (price, quality, social value and so on).
Evaluation split and conditions of participation as published; the tender pack may add morei
How this buyer will score bids.
The evaluation criteria and weights exactly as published on the notice, grouped by family (price, quality, social value and so on).
Published award criteria (2)
- Quality: 100
- Price: 0
Procedure terms & legal framework
From the official record · publisher note attached- Procedure method
- Open procedure
- Legal basis
- CELEX · 32014L0024 Public Contracts Regulations 2015 (Directive 2014/24/EU)
- Procurement category
- Services
- Notice status
- Awarded
- Procurement threshold
- Unspecified in notice
- Regulatory regime
- Standard
- Commercial structure
- Stand-alone contract (no framework)
- Competition type
- Competitive procedure
- GPA / WTO covered
- Yes (GPA)
- Recurring procurement
- No (one-off requirement)
- First published
- 24 Sept 2024, 14:40 BST
- Last source update
- 29 Jun 2026, 10:42 BST
- Award evaluation window
- 7 Nov 2024 – …
- Authority reference
C298937- FTS notice number
2026/S 000-060637- Classification (CPV)
- Delivery area
- Official registry OCID
ocds-h6vhtk-049d59Find a Tender
Publisher note: This is a Provider Selection Regime (PSR) intention to award notice. The awarding of this contract is subject to the Health Care<br/>Services (Provider Selection Regime) Regulations 2023. For the avoidance of doubt, the provisions of the Public Contracts Regulations 2015 do not apply to this award. The standstill period begins on the day after the publication of this notice. Representations by providers must be made to the relevant authority by Tuesday 11 March 2025. This contract has not yet formally been awarded; this notice serves as an intention to award under the PSR.’ Representations should be sent to [email protected]. The award decision-makers is NHS England National Commissioning Group (NCG); - The Key Criteria used for the award:<br/>Quality & innovation: 35%<br/>Value: Pass or Fail<br/>Integration, Collaboration<br/>& Service Sustainability: 26%<br/>Improving Access,<br/>Reducing Health Inequalities and Facilitating<br/>Choice: 24%<br/>Social Value: 15%<br/>The rationale for choosing the provider(s) were based on them being the highest scoring bidders, which was approved by NHS England governance following a comprehensive evaluation process.
How it was run
Official noticeTender documents are also served through a separate tool: https://health-family.force.com/s/Welcome ↗
- Submission deadline
- 7 Nov 2024, 17:00 GMT
- Submission channel
- {"electronicSubmission","written"}
- Accepted languages
- en
- Bids opened
- 7 Nov 2024, 18:00 GMT
Timeline
7 Nov 2024 → 29 Jun 2026 · 4 dates- Submission deadline7 Nov 2024, 17:00 GMT
- Bids opened7 Nov 2024, 18:00 GMT
- Bids must remain valid until1 May 2025, 23:59 BST
- Notice published119 days ago29 Jun 2026, 10:42 BST
Notice history
1 event · 3 releases on Find a Tender- Status changed to complete27 Feb 2025, 16:47 GMT
Published amendments (1)
This is a Provider Selection Regime (PSR) confirmation of contract award notice. This contract has been awarded under the Health Care Services (Provider Selection Regime) Regulation 2023. For the avoidance of doubt, the provisions of the Procurement Act Regulations 2023 do not apply to this award. This contract had now been formally awarded using the competitive process.Date of contract award: …
Commercial outcome & contract awards
Published awards, contracts and bid statistics, not a forecast| Awarded to | Value | Date | Status |
|---|---|---|---|
| Lot 2 · Midlands1 award | |||
| University Hospitals Birmingham NHS Foundation Trust | £1,470,000 † | — | Awarded |
| Lot 3 · North West1 award | |||
| THE CLATTERBRIDGE CANCER CENTRE NHS FOUNDATION TRUST | £1,470,000 † | — | Awarded |
2 further award records carry no date or value.
Contracts
Midlands · University Hospitals Birmingham NHS Foundation Trust
- Signed
- 25 Feb 2025
- Value
- £1,470,000
- Status
- active
North West · THE CLATTERBRIDGE CANCER CENTRE NHS FOUNDATION TRUST
- Signed
- 25 Feb 2025
- Value
- £1,470,000
- Status
- active
Bid statistics published by the authority
| Lot | Bids | SME | VCSE | Valid bid range |
|---|---|---|---|---|
| 2 · Midlands | 1bids | — | — | — |
| 3 · North West | 2bids | — | — | — |
Contracting authority & participating public bodies
Dispute resolution & review bodies
- NHS Arden and GEM CSUReview body
Bidders & participating suppliers
2 commercial parties on the notice- THE CLATTERBRIDGE CANCER CENTRE NHS FOUNDATION TRUSTAwarded supplier
- University Hospitals Birmingham NHS Foundation TrustAwarded supplier
Official documents & specifications
Official links; attachments are not copiedNo document links were published on the notice.